Hansa Biopharma: Notes on KOL Comments on ConfideS - Redeye
Bildkälla: Stockfoto

Hansa Biopharma: Notes on KOL Comments on ConfideS - Redeye

Redeye comments on the KOL event 12 November. The KOL's opinions strenghten our conviction in a successful US launch of imlifidase.

Redeye comments on the KOL event 12 November. The KOL's opinions strenghten our conviction in a successful US launch of imlifidase.
Börsvärldens nyhetsbrev